Bio3 Research srl


Overview

Bio3 has 15 patents on the use of the protein HMGB1 for (a) connective tissue regeneration (diabetic foot ulcers, wound healing, cartilage repair and bone regeneration), and (b) treatment of cardiovascular disorders (atherosclerosis, restenosis, arterial stenosis, and vasculitis). Bio3’s products target significant markets with unmet needs. Bio3’s dietary supplement, Biocysan, treats anemia and oxidative stress in chronic kidney disease patients.

Management Team

CEO

Francesco Paolo Pilato

Dr. Pilato, educated as a chemist, served for more than thirty years at the top executive level in the pharmaceutical and diagnostic industry. Much of his professional experience was in the international arena. In the seventies, after a short experience at Lederle Labs, he was appointed Resident Area Manager Middle East at Farmitalia. Later he moved to Japan as Assistant to the Managing Director of Nippon Farmitalia. After his return to Farmit

John Piret